<DOC>
	<DOC>NCT02405221</DOC>
	<brief_summary>This study will be looking at what dose of the TA-CIN/GPI-0100 vaccine is safe and effective in patients with a history of HPV16 associated cervical cancer.</brief_summary>
	<brief_title>Clinical Trial Safety and Feasibility of TA-CIN Vaccine in Combination With GPI-0100 Adjuvant in Patients With a History of HPV16 Associated Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1. Patients with HPV16 related stage IB1IV cervical cancer who completed definitive treatment within 3 years 2. Patients with no evidence of disease recurrence 3. Age â‰¥ 18 years 4. ECOG Performance Status of 0 to 1 5. Adequate organ function as defined by studyspecified laboratory tests 6. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug 7. Signed informed consent form 8. Willing and able to comply with study procedures 1. Currently have or have history of certain studyspecified heart, liver, kidney, lung, neurological, immune or other medical conditions 2. Systemically active steroid use 3. Prior HPV vaccination 4. Had surgery, chemotherapy, or radiation therapy within 28 days prior to receiving study drug 5. Another investigational product within 28 days prior to receiving study drug 6. Active or chronic HIV, HBV, or HCV infection 7. Pregnant or lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>